ROS Therapeutics Holding ApS
CVR 39507056 · Private limited company (ApS) · Active · Low risk
ROS Therapeutics Holding ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry ikke-finansielle holdingselskaber. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 8 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -117k and a net result of DKK -27k. CEO: Hanne Damgaard Jensen.
Bankruptcy risk for ROS Therapeutics Holding ApS
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39507056
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Ikke-finansielle holdingselskaber (642120)
Bankruptcies in the industry: Ikke-finansielle holdingselskaber - Share capital
- DKK 100k
- Auditor
- BDO Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 8 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -292.9% |
| Current ratio | 26% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 167 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -11k | DKK -13k | DKK -13k |
| Net profit | DKK -27k | DKK -14k | DKK -14k |
| Equity | DKK -117k | DKK -256k | DKK -243k |
| Total assets | DKK 40k | DKK 19k | DKK 26k |
| Cash | DKK 40k | DKK 2,752 | – |
| Short-term debt | DKK 157k | DKK 275k | – |
| Avg. employees | 0 | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · BDO Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 174 | ||
| 1 Jan 2024 – 31 Dec 2024 | 170 | ||
| 1 Jan 2023 – 31 Dec 2023 | 154 | ||
| 1 Jan 2022 – 31 Dec 2022 | 171 | ||
| 1 Jan 2021 – 31 Dec 2021 | 177 | ||
| 1 Jan 2020 – 31 Dec 2020 | 172 | ||
| 1 Jan 2019 – 31 Dec 2019 | 132 | ||
| 23 Apr 2018 – 31 Dec 2018 | 120 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Hanne Damgaard Jensen | Current | |
| Board | Hanne Damgaard Jensen | ||
| Board | Christian Philip Hansen | ||
| Board | Mads Hartvig Clausen | ||
| Board | Jon Bondebjerg | ||
| Owner (10%) | SPORCON LIFESCIENCE ADVISORS ApS | Current | |
| Owner (90%) | HDJ & LEJ Invest ApS | Current | |
| Owner (25%) | 2200 HOLDING ApS | ||
| Owner (25%) | Liltorp-Bondebjerg Invest ApS | ||
| Owner (67%) | HDJ & LEJ Invest ApS | ||
| Owner (25%) | Abihansen Holding IVS | ||
| Owner (25%) | ROS Therapeutics Holding ApS | ||
| Owner (15%) | ROS Therapeutics Holding ApS | ||
| Owner (10%) | ROS Therapeutics Holding ApS | ||
| Owner (5%) | Pebean Pharma ApS | ||
| Founder | 2200 HOLDING ApS | Current | |
| Founder | Liltorp-Bondebjerg Invest ApS | Current | |
| Founder | HDJ & LEJ Invest ApS | Current | |
| Founder | Abihansen Holding IVS | Current |
The CEOs' other companies
Hanne Damgaard Jensen – 6 other companies
- AZANTA A/S Active
- AZANTA DANMARK A/S Active
- AimVion A/S Opløst
- HDJ & LEJ Invest ApS Active
- MLMC Therapeutics ApS Active
- ROS Therapeutics ApS Opløst
Address history (0 moves)
| Ole Maaløes Vej 3, 2200 København N |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- ANTECH INVEST A/S København K
- NIELS BUCHHOLST A/S København Ø
- METROPOLITAN HOLDING ApS København S
- JOOST HOLDING ApS København K
- TENNECO HOLDINGS DANMARK ApS København V
- GENUA A/S København K
- AHM AF 1997 HOLDING ApS Nordhavn
- T. K. BOESEN HOLDING ApS København K
- Hallerup Group ApS København K
- B. EYDE-JØRGENSEN ApS København V
- BRØDR. JØRGENSEN HOLDING A/S København K
- GULDBERG EJENDOMS- OG INVESTERINGSSELSKAB A/S København N
Questions and answers about ROS Therapeutics Holding ApS
Has ROS Therapeutics Holding ApS gone bankrupt?
No, ROS Therapeutics Holding ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of ROS Therapeutics Holding ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the CEO of ROS Therapeutics Holding ApS?
Hanne Damgaard Jensen is the CEO of ROS Therapeutics Holding ApS.
Who is the auditor of ROS Therapeutics Holding ApS?
ROS Therapeutics Holding ApS most recently used BDO Statsautoriseret Revisionspartnerselskab.
When was ROS Therapeutics Holding ApS founded?
ROS Therapeutics Holding ApS was founded on 23 April 2018.
What is the equity of ROS Therapeutics Holding ApS?
Equity was DKK -117k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.